Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 28 June 2013, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £16.39 per Ordinary Share, and notional ADSs at a price of $49.95 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2013 to 30 June 2013:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
|
|
|
Sir Christopher Gent |
2,593.045 |
|
|
|
|
Professor Sir Roy Anderson |
552.929 |
|
|
|
|
Dr Stephanie Burns |
|
462.187 |
|
|
|
Stacey Cartwright |
438.530 |
|
|
|
|
Lynn Elsenhans |
|
831.937 |
|
|
|
Judy Lewent |
|
391.854 |
|
|
|
Sir Deryck Maughan |
|
1,083.369 |
|
|
|
Dr Daniel Podolsky |
|
873.536 |
|
|
|
Tom de Swaan |
514.796 |
|
|
|
|
Jing Ulrich |
|
291.379 |
|
|
|
Hans Wijers |
324.131 |
|
|
|
|
Sir Robert Wilson |
477.501 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2013.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 July 2013